China Merchants Securities: The 24Q1 Chinese medicine sector has steadily overcome high base pressure, and profit levels and dividends have improved markedly

The traditional Chinese medicine industry was slightly under pressure due to high base pressure in the short term, but the level of profit and dividends performed well. In the context of policies encouraging the inheritance, innovation and development of traditional Chinese medicine, along with the reform of state-owned enterprises and the implementation of catalytic events such as the basic drug catalogue, the traditional Chinese medicine sector is still cost-effective.

Zhitong FinanceMay 20 01:42 ET

Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Most readers would already be aware that Jiangsu Kanion PharmaceuticalLtd's (SHSE:600557) stock increased significantly by 15% over the past three months. We wonder if and what role the company's fi

Simply Wall StMay 9 19:14 ET

Kangyuan Pharmaceutical (600557.SH): A total cost of 17.34 million yuan to buy back 0.1733% of shares

Gelonghui, May 7, 丨 Kangyuan Pharmaceutical (600557.SH) announced that as of April 30, 2024, the company had repurchased a total of 1,013,600 shares, accounting for 0.1733% of the company's total share capital. The highest purchase price was 19.83 yuan/share, the lowest price was 16.27 yuan/share, and the total amount paid was 17,344,891.23 yuan (including transaction fees).

Gelonghui FinanceMay 7 06:27 ET

Jiangsu Kanion PharmaceuticalLtd's (SHSE:600557) Earnings May Just Be The Starting Point

Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) earnings announcement last week was disappointing for investors, despite the decent profit numbers. We have done some analysis and have found so

Simply Wall StApr 20 21:07 ET

Kangyuan Pharmaceutical (600557.SH): Net profit of 148 million yuan in the first quarter increased 4.67% year-on-year

Gelonghui, April 12 | Kangyuan Pharmaceutical (600557.SH) released its first quarter report. Operating revenue was 1,359 million yuan, up 0.48% year on year, net profit of 148 million yuan, up 4.67% year on year, after deducting non-net profit of 140 million yuan, up 0.20% year on year, with basic earnings per share of 0.26 yuan.

Gelonghui FinanceApr 12 05:31 ET

Is There An Opportunity With Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) 36% Undervaluation?

Key Insights The projected fair value for Jiangsu Kanion PharmaceuticalLtd is CN¥31.77 based on 2 Stage Free Cash Flow to Equity Current share price of CN¥20.20 suggests Jiangsu Kanion Pharmaceutica

Simply Wall StApr 8 23:40 ET